Postmarket Transformation Plan Update With FDA’s Don St. Pierre
This article was originally published in The Gray Sheet
Executive Summary
FDA's device center set out on an ambitious path last year to revamp the way it oversees product safety in what it is calling its 1"postmarket transformation" initiative
You may also be interested in...
New CDRH Decision Methods Will Be Put To The Test, Starting With Stents
Defining a "new science" for post-market surveillance is a top priority for the FDA device center's post-market group, according to the program's new leader
New CDRH Decision Methods Will Be Put To The Test, Starting With Stents
Defining a "new science" for post-market surveillance is a top priority for the FDA device center's post-market group, according to the program's new leader
FDA May Wield Prosecutorial Authority More Frequently
Device companies can expect more active legal prosecution by FDA for off-label and product safety issues as the agency improves its ability to track products on the market and as the activity of industry whistleblowers grows, according to government and agency staffers